Original Article

Changes of miR-130a and ET-1 and Their Predictive Value for In-Stent Restenosis after Percutaneous Coronary Intervention


Background: To explore the changes of miR-130a and endothelin -1 (ET-1) and their predictive value for in-stent restenosis (ISR) after percutaneous coronary intervention (PCI).

Methods: Overall, 253 patients with coronary heart disease (CHD) treated with PCI in Lianshui County People's Hospital, Huaian, China from April 2013 to May 2016 were selected. The changes of miR-130a and ET-1 levels before and after PCI were compared. The predictive value of miR-130a and ET-1 for ISR was analyzed by receiver operating characteristic (ROC) curves, and the correlation between ISR and miR-130a, ET-1 was analyzed by Kaplan-Meier (K-M) curve. The risk factors of ISR in CHD patients were evaluated by logistics regression analysis.

Results: The postoperative levels of miR-130a and ET-1 were significantly increased (P<0.05). The levels of miR-130a and ET-1 in peripheral blood of patients with ISR were higher than those in patients without ISR (P<0.05). The ROC curves showed that the area under curve (AUC), sensitivity, specificity and critical value of miR-130a in predicting ISR were respectively 0.912, 92.02%, 73.47%, 1.457 pmol/L, and those of ET-1 were 0.814, 87.63%, 63.27%, 2.245 pmol/L, respectively. The K-M curve showed that the incidence of ISR in patients with high expression of miR-130a or ET-1 was significantly higher than that in patients with low expression (P<0.05). miR-130a and ET-1 were independent risk factors for ISR (P<0.05).

Conclusion: MiR-130a and ET-1 have high predictive value for ISR after PCI and are independent risk factors for CHD patients, which are worthy of clinical application.

1. Mendis S, Puska P, Norrving B (2011). Global atlas on cardiovascular disease prevention and control. Geneva: World Health Organization.
2. Roger V L (2007). Epidemiology of myo-cardial infarction. Med Clin N Am, 91: 537-552.
3. Lloyd-Jones D, Adams RJ, Brown TM, et al (2007). Executive summary: heart disease and stroke statistics—2010 update: a re-port from the American Heart Associa-tion. Circulation, 121: 948-954.
4. Nichols M, Townsend N, Scarborough P, Rayner M (2014). Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J, 35: 2950-2959.
5. Organization WH (2007). Prevention of car-diovascular disease: guidelines for as-sessment and management of cardiovas-cular risk. Tetrahedron Lett, 54: 2817-2820.
6. Organization WH (2008). Preventing chronic diseases: a vital investment. Preventing Chronic Diseases A Vital Investment, 126: 95.
7. Katritsis DG, Ioannidis JPA (2008). Percu-taneous coronary intervention versus conservative therapy in nonacute coro-nary artery disease: a meta-analysis. Circu-lation, 111: 2906-2912.
8. Cassese S, Byrne RA, Tada T, Pinieck S, Joner M, Ibrahim T, King LA, Fusaro M, Laugwitz KL, Kastrati A (2014). Inci-dence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart, 100: 153-159.
9. He M, Gong Y, Shi J, Pan Z, Zou H, Sun D, Tu X, Tan X, Li J, Li W (2014). Plas-ma microRNAs as potential noninvasive biomarkers for in-stent restenosis. PloS One, 9: e112043.
10. Yu ZH, Wang HT, Tu C (2007). Diagnostic value of microRNA-143 in predicting in-stent restenosis for patients with lower extremity arterial occlusive disease. Eur J Med Res, 22: 2.
11. Chen Y, Gorski DH (2008). Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood, 111: 1217-1226.
12. Wu WH, Hu CP, Chen XP, Zhang WF, Li XW, Xiong XM, Li YJ (2011). Mi-croRNA-130a mediates proliferation of vascular smooth muscle cells in hyperten-sion. Am J Hypertens, 24: 1087-1093.
13. Ren Y, Zhang B, Jia DP, Hu K (2018). Ef-fects of miR-130a on viability and apop-tosis of rat basilar arterial smooth muscle cells. Chin J Pathophysiol, 34: 989-995.
14. Idris-Khodja N, Ouerd S, Mian MOR, Gornitsky J, Barhoumi T, Paradis P, Schiffrin EL (2016). Endothelin-1 over-expression exaggerates diabetes-induced endothelial dysfunction by altering oxida-tive stress. Am J Hypertens, 29: 1245-1251.
15. Xia ZY, Yang H, Qu HQ, Cheng WD, Wang LX (2011). Expression of P-selectin, von Willebrand and endothelin-1 after carotid artery stenting. Vasa, 40: 199-204.
16. Fu CG, Gao ZY, Wang PL (2012). Study on the diagnostic criteria for coronary heart disease patients of blood stasis syn-drome. Zhongguo Zhong Xi Yi Jie He Za Zhi, 32: 1285.
17. Hirose S, Ashikaga T, Hatano Y, Yoshikawa S, Sasaoka T, Maejima Y, Isobe M (2016). Treatment of in-stent restenosis with ex-cimer laser coronary angioplasty: benefits over scoring balloon angioplasty alone. Lasers Med Sci, 31: 1691-1696.
18. Poerner TC, Duderstadt C, Goebel B, Kretzschmar D, Figulla HR, Otto S (2017). Fractional flow reserve-guided coronary angioplasty using paclitaxel-coated balloons without stent implanta-tion: feasibility, safety and 6-month re-sults by angiography and optical coher-ence tomography. Clin Res Cardiol, 106: 18-27.
19. Andreini D, Mushtaq S, Pontone G, et al (2018). TCT-458 Additional Diagnostic Value of CT Perfusion over Coronary CT Angiography in Stented Patients with Suspected In-stent Restenosis or Coro-nary Artery Disease Progression: AD-VANTAGE study. Preliminary Results. J Am Coll Cardiol, 72: B184.
20. Li Z, Li Y, Zhang T, Miao W, Su G (2016). Comparison of the influence of ticagrelor and clopidogrel on inflammatory bi-omarkers and vascular endothelial func-tion for patients with ST-segment eleva-tion myocardial infarction receiving emergency percutaneous coronary inter-vention: study protocol for a randomized controlled trial. Trials, 17: 75.
21. Song XW, Shan DK, Chen J, Jing Q (2014). miRNAs and lncRNAs in vascular injury and remodeling. Sci China Life Sci, 57: 826-835.
22. Montezano AC, Cat AND, Rios FJ, Touyz RM (2014). Angiotensin II and vascular injury. Curr Hypertens Rep, 16: 431.
23. Santulli G (2015). microRNAs distinctively regulate vascular smooth muscle and en-dothelial cells: functional implications in angiogenesis, atherosclerosis, and in-stent restenosis. Adv Exp Med Biol, 887: 53-77.
24. Long G, Wang F, Duan Q, et al (2012). Human circulating microRNA-1 and mi-croRNA-126 as potential novel indicators for acute myocardial infarction. Int J Biol Sci, 8: 811–818.
25. Brock M, Haider TJ, Vogel J, et al (2015). The hypoxia-induced microRNA-130a controls pulmonary smooth muscle cell proliferation by directly targeting CDKN1A. Int J Biochem Cell Biol, 61: 129-137.
26. Planas-Rigol E, Terrades-Garcia N, Corbera-Bellalta M, et al (2017). En-dothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascu-lar remodelling and intimal hyperplasia in giant-cell arteritis. Ann Rheum Dis, 76: 1624-1634.
27. Chen N, Chen L, Jiang S, Wang Z, Liu T (2019). Predictive value of P selectin and endothelin 1 for vascular restenosis after interventional procedures for peripheral artery disease. Exp Ther Med, 17: 3907-3912.
IssueVol 49 No 3 (2020) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijph.v49i3.3142
Coronary heart disease Interventional therapy miR-130a Human In-stent restenosis Prediction

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
LIU H, QIAN H, MA J, DAI Q, JI M. Changes of miR-130a and ET-1 and Their Predictive Value for In-Stent Restenosis after Percutaneous Coronary Intervention. Iran J Public Health. 2020;49(3):463-471.